Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy

Affiliations

¹ Electrophysiology Section/Duke Center for Atrial Fibrillation, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina. Electronic address: james.daubert@duke.edu.
² Electrophysiology Section/Duke Center for Atrial Fibrillation, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina.

Free article

Editorial

James P Daubert et al. JACC Heart Fail. 2019 Aug.

Free article

. 2019 Aug;7(8):725-727.

doi: 10.1016/j.jchf.2019.05.011. Epub 2019 Jul 10.

¹ Electrophysiology Section/Duke Center for Atrial Fibrillation, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina. Electronic address: james.daubert@duke.edu.
² Electrophysiology Section/Duke Center for Atrial Fibrillation, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina.

No abstract available

Keywords: ICD; implantable defibrillator; non-ischemic dialated cardiomyopathy; risk prediction; sudden cardiac death.

Comment on

Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.
Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbæk L, Bruun NE, Eiskjær H, Wiggers H, Brandes A, Thøgersen AM, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, Signorovitch J, Køber L, Thune JJ. Kristensen SL, et al. JACC Heart Fail. 2019 Aug;7(8):717-724. doi: 10.1016/j.jchf.2019.03.019. Epub 2019 Jul 10. JACC Heart Fail. 2019. PMID: 31302052